Munenori Kawai

Dr. Munenori Kawai

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MKMunenori Kawai
Munenori Kawai
AFAkihisa Fukuda
Akihisa Fukuda
RORyo Otomo
Ryo Otomo
SOShunsuke Obata
Shunsuke Obata
KMKosuke Minaga
Kosuke Minaga
HSHiroshi Seno
Hiroshi Seno
Background: Pancreatic cancer is often diagnosed at advanced stages, and early-stage diagnosis of pancreatic cancer is difficult because of nonspecific symptoms and lack of available biomarkers. Methods: We performed comprehensive serum miRNA sequencing of 212 pancreatic cancer patient samples from 14 hospitals and 213 non-cancerous healthy control samples. We randomly classified the pancreatic cancer and control samples into two cohorts: a training cohort (N = 185) and a validation cohort (N = 240). We created ensemble models that combined automated machine learning with 100 highly expressed miRNAs and their combination with CA19-9 and validated the performance of the models in the independent validation cohort. Results: The diagnostic model with the combination of the 100 highly expressed miRNAs and CA19-9 could discriminate pancreatic cancer from non-cancer healthy control with high accuracy (area under the curve (AUC), 0.99; sensitivity, 90%; specificity, 98%). We validated high diagnostic accuracy in an independent asymptomatic early-stage (stage 0-I) pancreatic cancer cohort (AUC:0.97; sensitivity, 67%; specificity, 98%). Conclusions: We demonstrate that the 100 highly expressed miRNAs and their combination with CA19-9 could be biomarkers for the specific and early detection of pancreatic cancer.

2 June 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMunenori Kawai
Munenori Kawai
AFAkihisa Fukuda
Akihisa Fukuda
MIMunehiro Ikeda
Munehiro Ikeda
KIKei Iimori
Kei Iimori
KMKenta Mizukoshi
Kenta Mizukoshi
HSHiroshi Seno
Hiroshi Seno
Mutations in Polybromo 1 ( PBRM1 ), a subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, are frequently observed in several cancers, including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrated that pancreas-specific loss of Pbrm1 in mice harboring Kras mutations and Trp53 deletions accelerated the development of poorly differentiated PDAC, epithelial-mesenchymal transition (EMT), and metastasis, resulting in worsened prognosis. Pbrm1 loss in preexisting PDAC shifted the tumor grade from a well- to a poorly differentiated state and elevated vimentin expression. Pbrm1 -null PDAC exhibited downregulation of apical junction genes and upregulation of EMT pathway genes, including the vimentin and squamous molecular subtype signature genes. Mechanistically, PBRM1 bound to the vimentin gene promoter and directly downregulated its expression. Furthermore, suppression of vimentin in Pbrm1 -null PDAC cells reversed the dedifferentiation phenotype and reduced EMT and metastasis. Consistently, reduced PBRM1 expression correlated with high vimentin expression, poorly differentiated histology, a high recurrence rate, and reduced overall survival in human PDACs. Additionally, PDAC with PBRM1 deletion was associated with the aggressive squamous molecular subtype. Our data established PBRM1 as a tumor suppressor that controls tumor grade and metastasis of PDAC by regulating vimentin expression.

8 June 2021 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MKMunenori Kawai
Munenori Kawai
CKChiharu Kawanami
Chiharu Kawanami
AFAkihisa Fukuda
Akihisa Fukuda
HSHiroshi Seno
Hiroshi Seno

3 September 2020 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MKMunenori Kawai
Munenori Kawai
AFAkihisa Fukuda
Akihisa Fukuda
AYAkitada Yogo
Akitada Yogo
TKTakumi Kozu
Takumi Kozu
KTKaoru Taira
Kaoru Taira
HSHiroshi Seno
Hiroshi Seno

2 July 2021 in JGH Open
Verified
Journal Article
Open access
PDF file
MKMunenori Kawai
Munenori Kawai
NGNaoki Goda
Naoki Goda
MNMitsuhiro Nikaido
Mitsuhiro Nikaido
AFAkihisa Fukuda
Akihisa Fukuda
We herein describe an extremely rare case of gastric granular cell tumor (GCT). The gastric submucosal tumor showed a central tiny depression on the surface with a molar tooth-like appearance on esophagogastroduodenoscopy. Our case highlights that gastric GCT should be considered as differential diagnosis of gastric submucosal tumors.

5 June 2026 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
YOYusuke Okamoto
Yusuke Okamoto
KIKenichi Ishiyama
Kenichi Ishiyama
KCKazuhisa Chonabayashi
Kazuhisa Chonabayashi
JKJunya Kanda
Junya Kanda
MKMunenori Kawai
Munenori Kawai
ATAkifumi Takaori
Akifumi Takaori
T-cell large granular lymphocyte leukaemia (T-LGLL) is a chronic lymphoproliferative disorder often associated with pure red cell aplasia (PRCA). We report a unique case of a woman in her 50s presenting with PRCA secondary to T-LGLL, in which targeted next-generation sequencing identified a somatic STAT3 P715L mutation. This variant, previously described only in germline mutation in STAT3 gain-of-function syndrome, has not been reported as a somatic mutation in T-LGLL. Immunohistochemical analysis revealed constitutive STAT3 (signal transducer and activator of transcription 3) activation in clonal CD8 + T cells, suggesting a pathogenic role for the P715L mutation. The patient responded to ciclosporin therapy with gradual haematological improvement and became transfusion-independent within 6 months. This case highlights the importance of molecular profiling in T-LGLL presentations and expands the known mutational spectrum of STAT3 . It also raises the possibility that non-SH2 (Src homology 2) domain STAT3 mutations may contribute to disease pathogenesis and influence treatment response in T-LGLL.